Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Glenmark Pharmaceuticals Limited (GLENMARK.NS)
INR2,297.40
-7.70 (-0.33%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Glenmark House 400099
Mumbai, IN
Mumbai, IN
CEO
Glenn Mario Saldanha
Website
glenmarkpharma.com
IPO
2002-07-01
ISIN INE935A01035
Also trades on
Bombay Stock Exchange · GLENMARK.BO (INR)
National Stock Exchange of India · GLENMARK.NS (INR)
Description
Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR2,297.40
-7.70 (-0.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
711.8K
Beta
0.26
Float Shares
141.58M
Free Float %
50.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.24% | -5.20% | -8.04% | +3.02% | +13.36% | +8.16% | +46.99% | +261.09% | +270.14% | +158.96% | +8,016.52% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,297.40
DCF (Unlevered)
804.17
-65.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.51
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+27.1% ★ Q1'26: +18.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+30.0% ★ Q1'26: +6,575.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+16.0% Q1'26: +61.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+23.6% ★ Q1'26: +16.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+27.6% ★ Q1'26: +19.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: -2.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.13× ★ Q1'26: 0.19× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2003 actual |
Mar 2005 actual |
Mar 2006 actual |
Mar 2007 actual |
Mar 2008 actual |
Mar 2009 actual |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 8 Rev. Ana. 6 EPS Ana. |
Mar 2027 7 Rev. Ana. 8 EPS Ana. |
Mar 2028 7 Rev. Ana. 8 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.23B
est.
|
6.12B
est: 5.79B (+5.8%)
|
7.58B
est: 7.20B (+5.2%)
|
12.52B
est: 10.98B (+13.9%)
|
20.09B
est: 18.45B (+8.9%)
|
21.16B
est: 22.09B (-4.2%)
|
25.01B
est: 24.73B (+1.1%)
|
29.49B
est: 29.76B (-0.9%)
|
40.21B
est: 38.63B (+4.1%)
|
49.76B
est: 49.70B (+0.1%)
|
59.45B
est: 60.21B (-1.3%)
|
65.56B
est: 66.95B (-2.1%)
|
75.73B
est: 72.97B (+3.8%)
|
90.79B
est: 95.69B (-5.1%)
|
90.74B
est: 90.99B (-0.3%)
|
98.65B
est: 99.18B (-0.5%)
|
106.57B
est: 105.24B (+1.3%)
|
109.44B
est: 110.11B (-0.6%)
|
123.05B
est: 121.69B (+1.1%)
|
116.56B
est: 129.15B (-9.7%)
|
126.45B
est: 128.61B (-1.7%)
|
133.63B
est: 134.33B (-0.5%)
|
170.80B
146.15B – 192.20B
+27.1% YoY
|
163.50B
151.95B – 168.66B
-4.3% YoY
|
183.68B
166.33B – 189.78B
+12.3% YoY
|
| EBITDA |
492.61M
est.
|
1.60B
est: 792.51M (+102.1%)
|
1.51B
est: 1.57B (-4.0%)
|
4.42B
est: 1.84B (+140.3%)
|
8.46B
est: 6.13B (+38.0%)
|
5.12B
est: 8.62B (-40.6%)
|
6.69B
est: 2.57B (+160.4%)
|
7.37B
est: 4.02B (+83.4%)
|
7.33B
est: 5.39B (+36.0%)
|
10.64B
est: 5.64B (+88.8%)
|
12.13B
est: 8.48B (+42.9%)
|
8.99B
est: 8.24B (+9.1%)
|
13.03B
est: 7.28B (+78.9%)
|
16.03B
est: 13.82B (+16.0%)
|
14.66B
est: 15.39B (-4.8%)
|
15.86B
est: 12.54B (+26.4%)
|
14.91B
est: 16.03B (-7.0%)
|
19.45B
est: 12.04B (+61.5%)
|
19.12B
est: 13.11B (+45.9%)
|
14.29B
est: 14.19B (+0.7%)
|
18.30B
est: 19.62B (-6.7%)
|
21.68B
est: 20.50B (+5.7%)
|
26.05B
22.29B – 29.32B
+27.1% YoY
|
24.94B
23.18B – 25.72B
-4.3% YoY
|
28.02B
25.37B – 28.95B
+12.3% YoY
|
| EBIT |
426.98M
est.
|
1.44B
est: 749.84M (+91.7%)
|
1.27B
est: 1.73B (-26.9%)
|
4.00B
est: 1.74B (+129.9%)
|
7.75B
est: 6.45B (+20.1%)
|
4.09B
est: 8.73B (-53.1%)
|
5.48B
est: 2.63B (+108.0%)
|
6.42B
est: 6.00B (+7.0%)
|
6.35B
est: 6.46B (-1.7%)
|
9.78B
est: 7.83B (+24.9%)
|
11.06B
est: 10.75B (+2.9%)
|
7.83B
est: 9.88B (-20.8%)
|
11.81B
est: 8.35B (+41.5%)
|
14.60B
est: 14.59B (+0.1%)
|
13.16B
est: 13.90B (-5.3%)
|
12.60B
est: 13.82B (-8.9%)
|
12.98B
est: 15.13B (-14.2%)
|
17.16B
est: 13.94B (+23.1%)
|
18.40B
est: 15.18B (+21.2%)
|
11.38B
est: 16.43B (-30.7%)
|
14.46B
est: 17.00B (-15.0%)
|
19.07B
est: 17.77B (+7.3%)
|
22.58B
19.32B – 25.41B
+27.1% YoY
|
21.61B
20.09B – 22.30B
-4.3% YoY
|
24.28B
21.99B – 25.09B
+12.3% YoY
|
| Net Income |
440.37M
est.
|
1.07B
est: 1.33B (-19.4%)
|
879.76M
est: 1.33B (-34.0%)
|
3.10B
est: 1.34B (+131.0%)
|
6.32B
est: 5.21B (+21.4%)
|
1.93B
est: 7.57B (-74.4%)
|
3.31B
est: 2.15B (+54.2%)
|
4.58B
est: 3.90B (+17.3%)
|
4.60B
est: 5.88B (-21.7%)
|
6.20B
est: 5.84B (+6.1%)
|
5.42B
est: 7.49B (-27.6%)
|
4.75B
est: 6.13B (-22.5%)
|
7.02B
est: 5.20B (+35.0%)
|
9.16B
est: 8.80B (+4.1%)
|
8.04B
est: 8.72B (-7.8%)
|
9.25B
est: 8.49B (+9.0%)
|
7.76B
est: 9.80B (-20.9%)
|
9.70B
est: 8.22B (+17.9%)
|
9.42B
est: 8.96B (+5.2%)
|
2.97B
est: 2.55B (+16.7%)
|
-15.02B
est: -15.73B (+4.5%)
|
10.47B
est: 13.53B (-22.6%)
|
20.53B
6.50B – 48.19B
+51.8% YoY
|
22.86B
19.13B – 27.16B
+11.3% YoY
|
27.23B
23.71B – 30.58B
+19.1% YoY
|
| SGA |
849.45M
est.
|
1.51B
est: 1.49B (+1.0%)
|
2.12B
est: 1.89B (+12.1%)
|
3.25B
est: 3.24B (+0.2%)
|
4.57B
est: 5.45B (-16.1%)
|
6.98B
est: 5.45B (+28.1%)
|
7.84B
est: 6.97B (+12.5%)
|
—
est: 8.03B (-100.0%)
|
—
est: 6.62B (-100.0%)
|
16.31B
est: 7.98B (+104.2%)
|
19.41B
est: 9.60B (+102.2%)
|
15.45B
est: 24.12B (-35.9%)
|
19.22B
est: 29.53B (-34.9%)
|
23.60B
est: 38.09B (-38.0%)
|
25.15B
est: 33.70B (-25.4%)
|
28.74B
est: 39.73B (-27.7%)
|
28.63B
est: 21.79B (+31.4%)
|
28.10B
est: 34.49B (-18.5%)
|
29.18B
est: 37.56B (-22.3%)
|
31.83B
est: 40.66B (-21.7%)
|
34.46B
est: 33.83B (+1.9%)
|
36.81B
est: 35.35B (+4.2%)
|
44.92B
38.44B – 50.55B
+27.1% YoY
|
43.00B
39.96B – 44.36B
-4.3% YoY
|
48.31B
43.75B – 49.91B
+12.3% YoY
|
| EPS |
1.56
est.
|
4.49
est: 4.78 (-6.1%)
|
3.64
est: 8.61 (-57.7%)
|
12.99
est: 9.79 (+32.7%)
|
25.80
est: 23.86 (+8.1%)
|
7.70
est: 15.28 (-49.6%)
|
12.40
est: 12.76 (-2.8%)
|
16.78
est: 17.50 (-4.1%)
|
17.03
est: 19.98 (-14.7%)
|
22.91
est: 22.97 (-0.3%)
|
20.01
est: 26.39 (-24.2%)
|
17.52
est: 25.61 (-31.6%)
|
25.01
est: 30.26 (-17.4%)
|
32.46
est: 52.92 (-38.7%)
|
28.49
est: 29.59 (-3.7%)
|
32.78
est: 29.52 (+11.0%)
|
27.50
est: 25.19 (+9.2%)
|
34.38
est: 32.76 (+5.0%)
|
33.37
est: 38.78 (-14.0%)
|
-6.01
est: 33.66 (-117.9%)
|
-67.30
est: -55.77 (-20.7%)
|
37.11
est: 49.57 (-25.1%)
|
98.32
23.04 – 170.77
+98.3% YoY
|
82.33
67.77 – 96.25
-16.3% YoY
|
97.67
84.03 – 108.37
+18.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-01 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
32.67B
OE per share TTM
115.98
Owner's Yield
5.26%
Maintenance CapEx ratio
57.69%
Maint CapEx / Avg PPE
32.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.03% | 1.87M | 0.17% |
| 2 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.03% | 1.87M | 0.17% |
| 3 | Schwab Emerging Markets Equity ETF SCHE | 0.03% | 4.10M | 0.06% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.03% | 404.5K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.03% | 912.5K | 0.26% |
| 6 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.03% | 172.2K | 0.40% |
| 7 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.01% | 362.3K | 0.04% |
| 8 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 80.7K | 0.24% |
| 9 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 80.7K | 0.24% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 72.4K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
2.67M
Shares Outstanding
282.20M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Glenn Mario Saldanha | Chairman, MD & Chief Executive Officer | 181M | male |
| Cherylann Maria Pinto | Executive Director of Corporate Services & Executive Director | 62M | female |
| Brijlal Motwani | President & Chief Quality Officer | — | male |
| Christoph Stoller | President and Business Head of Europe & Emerging Markets | — | male |
| Harish Vinayak Kuber | Company Secretary & Compliance Officer | — | male |
| Indrajit Bose | President & Chief Quality Officer | — | male |
| Marc T. Kikuchi | President and Business Head of North America | — | male |
| Alind Sharma | President and Chief Human Resources Officer | — | male |
| Ulhas R. Dhuppad | President & Head of Global Pharmaceutical Development | — | male |
| Alok Malik | President & Business Head of India Formulations | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GLENMARK.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
